Comparative effectiveness of mirikizumab and risankizumab in patients with ulcerative colitis: A propensity-matched cohort study - PubMed
3 hours ago
- #Comparative Effectiveness
- #Ulcerative Colitis
- #Anti-IL23 Therapy
- Mirikizumab showed lower corticosteroid use (31.9% vs. 44.4%) and higher fecal calprotectin response compared to risankizumab in ulcerative colitis patients.
- No difference was found in therapy change or colectomy rates between the two treatments; adverse events were low.
- The study suggests mirikizumab may be more effective for inducing remission, especially in bio-exposed patients.